Review Article
The Potential Role of Donepezil for the Treatment of Dementia w ith Lewy Bodies
Norifumi Tsuno*
Department of Neuropsychiatry, Faculty of medicine, Kagawa University, Kagawa, Japan
- Corresponding Author:
- Norifumi Tsuno
Department of Neuropsychiatry, Faculty of medicine
Kagawa University 1750-1, Ikenobe, Miki-cho
Kita-gun, Kagawa 761-0793, Japan
Tel: 81-87-891-2166
Fax: 81-87-891-2168
E-mail: tsuno@med.kagawa-u.ac.jp
Received date: January 24, 2016; Accepted date: February 25, 2016; Published date: March 02, 2016
Citation: Tsuno N (2016) The Potential Role of Donepezil for the Treatment of Dementia with Lewy Bodies. J Alzheimers Dis Parkinsonism 6:214. doi:10.4172/2161-0460.1000214
Copyright: © 2016 Tsuno N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Dementia with Lewy bodies (DLB) is a common form of dementia in the elderly and constitutes the second largest group of patients with degenerative dementia. To date, on the one hand, four cholinesterase inhibitors (ChEIs) have been approved for the treatment of Alzheimer’s disease (AD). On the other hand, there are no drug for approved for the treatment of DLB. However clinical benefits and good tolerability have recently been reported in several clinical trials of cholinesterase inhibitors (ChEIs), particularly donepezil. This review describes various aspects of donepezil, including basic pharmacology and pharmacokinetics, with the primary focus on the clinical work.